Search Results - "Imber, B. S."

A PHASE I STUDY OF SPLIT‐COURSE BRIDGING RADIOTHERAPY (SC‐BRT) PRIOR TO COMMERCIAL CD19 CAR T‐CELL THERAPIES FOR PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL LYMPHOMAS by Imber, B. S., Yahalom, J., Palomba, M. L.

Get full text

Evolving consolidation patterns and modern outcomes for a large longitudinal cohort of primary CNS lymphoma patients by Imber, B. S., Tringale, K., White, C., Zhang, Z., Scordo, M., Yahalom, J., Grommes, C.

Get full text

A single‐center experience of low‐dose radiotherapy for primary extranodal marginal zone lymphoma of bronchus‐associated lymphoid tissue (BALT) by Freret, M. E., Tringale, K. R., Imber, B. S., Joffe, E., Yahalom, J., Hajj, C.

Get full text

PRIMARY HEPATIC LYMPHOMA: ROLE OF LOW‐DOSE RADIOTHERAPY AND PAIRED LITERATURE REVIEW by Ma, J., Daou, R., Eid, J. Bou, Lee, J., Fregonese, B., El‐Khoury, J., Wijetunga, N. A., Imber, B. S., Yahalom, J., Hajj, C.

Get full text

Radiation in a new era of Multiple Myeloma management: Patterns of utilization, clinical, radiologic, and biochemical outcomes, and possible genomic correlates of response by Dreyfuss, A. D., Fregonese, B., Ma, J., Reith, S., Cederquist, G., Hubbeling, H., Tringale, K. R., Wijetunga, N A., Usmani, S., Hajj, C., Imber, B. S., Yahalom, J.

Get full text

Multicenter experience with radiotherapy for relapse after chimeric antigen receptor T cell therapy in non‐Hodgkin lymphoma by Hubbeling, H., Figura, N., Ladbury, C., Keit, E. R., Chew, J., Fregonese, B., Silverman, E. A., Hajj, C., Shah, G., Kambhampati, S., Jain, M. D., Yang, J., Dandapani, S., Yahalom, J., Imber, B. S.

Get full text

Genetic Alterations in Follicular Lymphoma Predict Response to Very Low Dose Radiotherapy by Wijetunga, N. A., Lebow, E., Chan, A., Lee, J., Fregonese, B., Hajj, C., Cedarquist, G., Hubbeling, H., Ma, J., Sarkar, R., Tringale, K., Joffe, E., Dogan, A., Zelenetz, A. D., Salles, G., Imber, B. S., Yahalom, J.

Get full text

CNS radiotherapy as bridging prior to CAR T‐cell therapy for hematologic malignancies by Cederquist, G., Hubbeling, H., Tringale, K., Shah, G., Tomas, A. Alarcon, Shouval, R., Hajj, C., Fregonese, B., Lee, J., Dahi, P. B., Lin, R. J., Palomba, M. L., Perales, M., Salles, G., Falchi, L., Grommes, C., Scordo, M., Yahalom, J., Imber, B. S.

Get full text

DYNAMICS OF RADIOMIC FEATURES FOLLOWING BRIDGING THERAPY DETERMINE CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T‐CELL THERAPY OUTCOME by Imber, B. S., Silverman, E. A., Leithner, D., Hubbeling, H., Shah, G. L., Fregonese, B., Sanin, B. W., Tomas, A. A., Parascondola, A., Saldia, A., Landego, I., Dahi, P. B., Giralt, S., Lin, R. J., Scordo, M., Salles, G., Yahalom, J., Palomba, M. L., Schoder, H., Perales, M., Shouval, R.

Get full text

A Proof-of-Principle Study of Split-Course Bridging Radiotherapy Prior to Commercial CD19 CAR T-Cell Therapies for Patients With Relapsed or Refractory B-Cell Lymphomas by Imber, B.S., Palomba, M.L., Yahalom, J.

“…Chimeric antigen receptor T-cell therapies (CART) have revolutionized the treatment of aggressive B-cell lymphomas. Bridging radiotherapy (BRT) may serve two…”
Get full text

Prediction of Response to Very Low Dose Radiotherapy (4 Gy) in Mature B-Cell Lymphomas Using Metabolic Tumor Volume by Wijetunga, N.A., Imber, B.S., Lee, J., Hajj, C., Yahalom, J.

“…Numerous studies established the role of palliative very low dose radiotherapy (VLDRT) of only 4 Gy in 2 fractions for indolent non-Hodgkin's lymphoma (NHL)…”
Get full text

Heightened Sensitivity of Germline BRCA Mutant Patients Treated With Concurrent or Adjuvant PARP Inhibition and Radiotherapy for Brain Metastases by Santos, P., Imber, B.S., Lapen, K., Pike, L.R.G., Moss, N., Seidman, A.D., Beal, K.

“…Limited data exist regarding the effect of radiotherapy (RT) and poly (ADP-ribose) polymerase inhibition (PARPi) for brain metastases (BM). However, RT is…”
Get full text

“Big Boom” Radiation Treatment (RT) of 4 Gy Single Fraction: Is It an Acceptable Alternative to “Boom Boom” Radiation Treatment 2 Gyx2 Fractions for Non-Hodgkin Lymphomas (NHL)? by Hajj, C., Lee, J., Fregonese, B., Imber, B.S., Wijetunga, N.A., Yang, J.C., Casey, D.L., Yahalom, J.

“…RT plays an important role in the treatment of NHL. Early in the COVID-19 pandemic, in order to decrease patient and staff exposure to potential infection, the…”
Get full text

Patient-Reported Financial Toxicity Following Definitive Radiation Therapy for Localized Prostate Cancer by Gorovets, D., Tin, A., Vickers, A.J., Zelefsky, M.J., Ehdaie, B., Imber, B.S.

“…Financial toxicity is increasingly recognized but poorly characterized in the context of prostate cancer. The purpose of this study was to evaluate the…”
Get full text

VEGF Inhibition Reduces Intracranial Edema Following SRS of Brain Metastases From Renal Cell Carcinoma by Ma, J., Pike, L.R.G., Kotecha, R.R., Carlo, M., Imber, B.S., Yamada, Y., Moss, N., Beal, K.

“…Optimal control of brain metastases (BM) from renal cell carcinoma (RCC) with stereotactic radiosurgery (SRS) is critical as tyrosine kinase inhibitors (TKI)…”
Get full text

Outcomes and Relapse Patterns in Primary Central Nervous System Lymphoma: Longitudinal Analysis of 559 Patients Diagnosed From 1983-2020 by Tringale, K R, Scordo, M, Yahalom, J, White, C, Zhang, Z, Vachha, B, Cederquist, G, Schaff, L, DeAngelis, L, Grommes, C, Imber, B S

“…Contemporary outcomes and relapse patterns in primary CNS lymphoma (PCNSL) are lacking. We analyzed factors associated with relapse in a large cohort with…”
Get full text

Predictors of Response to Very Low Dose Radiotherapy (4Gy) for Indolent B-Cell Lymphomas: Is 4Gy Also Suitable for Potentially Curable Patients? by Imber, B.S., Chau, K.W., Lee, J., Chelius, M., Hajj, C., Wijetunga, N.A., Yang, J.C., Casey, D.L., Shepherd, A.F., Joffe, E., Zhang, Z., Yahalom, J.

“…Indolent non-Hodgkin lymphomas (iNHL), such as follicular lymphoma (FL) and marginal zone lymphoma (MZL) are highly radiosensitive. Previously untreated…”
Get full text

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023 by Wijetunga, N A, Lebow, E, Chan, A, Lee, J, Fregonese, B, Hajj, C, Cedarquist, G, Hubbeling, H, Ma, J, Sarkar, R, Tringale, K, Joffe, E, Dogan, A, Zelenetz, A D, Salles, G, Imber, B S, Yahalom, J

Get full text

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023 by Imber, B S, Silverman, E A, Leithner, D, Hubbeling, H, Shah, G L, Fregonese, B, Sanin, B W, Tomas, A A, Parascondola, A, Saldia, A, Landego, I, Dahi, P B, Giralt, S, Lin, R J, Scordo, M, Salles, G, Yahalom, J, Palomba, M L, Schoder, H, Perales, M, Shouval, R

Get full text

GRADE 3A FOLLICULAR LYMPHOMA CAN BE EFFECTIVELY CONTROLLED WITH VERY LOW DOSE RADIATION THERAPY by Imber, B.S., Chau, K., Goldberg, E., Joffe, E., Yahalom, J.

Get full text